Maxim Group Keeps Their Hold Rating on Can-Fite BioPharma

Maxim Group analyst Jason McCarthy maintained a Hold rating on Can-Fite BioPharma (NYSE: CANF) today. The company’s shares opened today at $1.26, close to its 52-week low of $1.18.

According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 9.5% and a 44.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.

Can-Fite BioPharma has an analyst consensus of Moderate Buy.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.75 and a one-year low of $1.18. Currently, Can-Fite BioPharma has an average volume of 172.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical company, which focuses on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases. Its products include pipeline drugs such as CF101, CF102 and CF602.